Physician profile
Robert A Rice
NPI 1588638019
$7,764.69
in general payments reported to CMS, 2019-2025
49 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,046 · 2020: $1,514 · 2021: $1,601 · 2022: $1,796 · 2023: $1,445 · 2024: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,808.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,023.01 | 2019-2024 | |
| Novo Nordisk INC | $963.03 | 2019-2024 | Ozempic, Rybelsus |
| Abbvie INC. | $618.21 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $544.81 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $402.00 | 2019-2024 | Camzyos, Eliquis |
| Glaxosmithkline, LLC. | $359.69 | 2019-2024 | Trelegy Ellipta |
| Astellas Pharma US INC | $350.75 | 2019-2024 | Veozah |
| Neurelis, INC. | $246.31 | 2023-2024 | Valtoco |
| Otsuka America Pharmaceutical, INC. | $231.07 | 2021-2023 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $222.02 | 2019-2024 | Farxiga, Breztri |
| Novartis Pharmaceuticals Corporation | $219.93 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $192.26 | 2019-2023 | Verquvo, Belsomra |
| Amgen INC. | $190.50 | 2019-2021 | |
| Amarin Pharma, INC. | $174.26 | 2019-2021 | |
| Lilly USA, LLC | $172.78 | 2019-2023 | Jardiance, Mounjaro |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.